Clinical Trials Directory
We are doing this study to find out if a drug called selinexor (the study drug) is a safe and effective option for maintenance therapy for patients with TP53 wild-type endometrial cancer who had a positive response to treatment with chemotherapy.
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is an option for patients with endometrial cancer. We want to know how well it works compared to standard chemotherapy.
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is a safe and effective option for people with cervical cancer. We want to see how well it works compared to the standard treatment for this diagnosis.
We are doing this study to find out if an experimental drug called Rina-S (the study drug) is a safe and effective option for ovarian cancer that is not improving with standard treatments.
We are using this registry to gather data about the use and safety of certain medical devices used in a part of the body called the aorta and/or iliac arteries, which are large blood vessels that run inside the chest, abdomen, and groin area. The name of the devices being looked at are the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device).
We are doing this study to collect data about the use and safety of the GORE TAG Conformable Thoracic Stent Graft®. This device is approved by the FDA for the endovascular repair of medical conditions of the aorta (the large blood vessel that runs inside the chest and abdomen).
We are dong this study to collect information about the use of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device). The TAMBE Device was approved by the FDA in 2024 for use in endovascular repair as a treatment for patients with thoracoabdominal and pararenal aortic aneurysms. We want to get data about how well the device performs in the patients who choose to get this implant.
We are doing this study is to find out if an investigational drug called imetelstat (the study drug) can lead to better outcomes in people who have myelofibrosis (MF) when it is compared to other available therapies.